Last updated: May 24, 2026
Pristiq (desvenlafaxine succinate extended-release) is supplied as a branded, prescription antidepressant product in the US. Its commercial supply chain is built around (1) drug substance and drug product manufacturers listed in FDA regulatory records and (2) specialty ingredient sourcing for controlled release oral solid dose manufacturing. Public supplier visibility is highest for the Finished Dosage Form (FDF) manufacturers through FDA labeling and regulatory submissions, while upstream excipient and polymer suppliers are typically not itemized in public records at the brand level.
Who manufactures Pristiq (desvenlafaxine ER) finished dosage form?
Answer: Pristiq’s finished-dose manufacturing is tied to the listed NDA holder and the specific FDF manufacturers named in FDA labeling and regulatory documentation for the marketed product strength and dosage form (oral tablets, extended release). These FDF sites are the primary “suppliers” for day-to-day wholesaler and pharmacy fulfillment.
What is the US regulatory entity behind Pristiq supply?
Answer: Pristiq is marketed in the US under an NDA by Pfizer Inc. The NDA holder controls market authorization while contracted manufacturers can produce either API (drug substance) or the finished dosage form.
What are the marketed dosage forms that define supply chain scope?
Pristiq is an oral extended-release solid. Supplier mapping differs by:
- Strengths: commonly marketed strengths include 25 mg, 50 mg, and 100 mg.
- Dosage form: extended-release tablets (film-coated or otherwise tablet-structured depending on packaging configuration).
Supplier implication: if a manufacturer site change occurs, it is generally strength- and product-version-specific, so “supplier” should be verified per NDC/strength for procurement.
Where do procurement teams verify finished dosage form suppliers?
Best-practice supplier verification uses:
- FDA product labeling (principal display panel and section describing manufacturing information)
- NDC directories linked to the corresponding labeler/marketed product configuration
- FDA chemistry and manufacturing controls references in NDA supplements (site changes, process changes, scale-up/tech transfer)
Which companies supply Pristiq drug substance (desvenlafaxine)?
Answer: The drug substance supplier is the API manufacturing site producing desvenlafaxine succinate used to feed FDF manufacturing. Unlike finished-dose suppliers, upstream API suppliers are often less visible in public commercial materials and require review of FDA regulatory submissions and inspection histories.
What does “drug substance supplier” mean for Pristiq purchasing?
- Desvenlafaxine succinate API produced under GMP
- Potential salt form and particle engineering controls that affect ER tablet performance
- Supply contracts that align batch-release testing and retest dating
How is API supply typically evidenced in public records?
Teams typically triangulate API supplier using:
- FDA application site information (manufacturing for API)
- Inspection and compliance data published by regulators
- Labeling references to manufacturing for drug substance if included
What excipients and extended-release components drive Pristiq tablet supply?
Answer: For Pristiq ER tablets, excipient supply is dominated by controlled-release polymer systems and tablet manufacturing inputs. Public disclosure rarely enumerates named excipient suppliers at brand level, so the procurement focus is on excipient categories and validated grades.
What excipient categories matter for ER tablet manufacturing?
Key inputs typically include:
- Matrix-forming or film-forming polymers for controlled release
- Tablet binders and disintegrants for consistent release and bioavailability
- Lubricants and anti-adherents for compression performance
- Coating systems that protect the tablet and manage dissolution characteristics
- Gelatin-free or reduced-gelatine requirements depending on local regulatory norms (not necessarily applicable to Pristiq tablet forms but relevant in broader procurement)
How do excipient supplier constraints affect ER drug supply risk?
ER formulations are sensitive to:
- Polymer viscosity and molecular weight distribution
- Particle size distribution and moisture control
- Batch-to-batch consistency affecting dissolution and release profile
Procurement implication: qualification typically locks the excipient grade and the supplier/manufacturing site used in validation batches.
What suppliers support Pristiq blistering, packaging, and distribution?
Answer: The market “supplier” for end-user delivery includes packaging and distribution chain participants tied to the labeler and NDC configuration. Packaging can be performed by contract packaging organizations under GMP with labeling controls.
Packaging-related supplier roles
- Tablet repackaging into bottling configurations (HDPE bottles, cartridges, cartons)
- Blister packaging where applicable for certain markets
- Serialization and labeling (where mandated)
- Distributor logistics and storage (temperature and humidity control for solids)
How to map packaging suppliers to NDCs
Packaging vendors are generally identifiable per:
- NDC labeler code and manufacturer code
- FDA listing linkages between labeler and site information
- Contract manufacturing and packaging acknowledgements in regulatory documents
What patent and exclusivity status affects supply competition and supplier switching?
Answer: Pristiq’s supply competition depends on whether generics or authorized alternatives can launch. Supplier switching is tied to regulatory approvals (ANDA) and any resulting procurement shifts.
When does Pristiq lose exclusivity?
Answer: Public timelines are driven by patent expiry and regulatory exclusivity mechanics tied to the NDA’s effective approval date. Supplier switching risk increases after:
- Primary patent expirations
- Secondary patent expiry (formulation, method-of-use, manufacturing)
- Loss of regulatory exclusivities that block ANDA approval
Do generics reduce reliance on brand suppliers?
Answer: Generic entry reduces the brand’s market share but does not eliminate the need for API/excipient-qualified supply chains. It can, however, change procurement leverage for API and excipients, especially if multiple approved ANDA products standardize materials.
What generic entry risks exist for Pristiq that could shift suppliers?
Answer: Generic (ANDA) entry risks depend on Paragraph IV challenges, patent settlements, and whether the generic can demonstrate bioequivalence and qualified dissolution for ER tablets.
How does Paragraph IV litigation affect supplier contracting?
When Paragraph IV litigation leads to a settlement, it can:
- Delay generic launch dates (post-settlement “at risk” timelines change)
- Lock brand supply by preserving market exclusivity for longer
- Drive parallel procurement actions by generic firms (API qualification and excipient sourcing)
What to track to anticipate supplier changes
- ANDA approvals and launch sequencing by strength
- Facility approvals and process validation acceptance
- Any FDA-approved manufacturing site transfers
How strong is Pristiq’s patent estate and what does it mean for “suppliers”?
Answer: The strength of the patent estate influences generic adoption rate, which influences brand supplier utilization. A stronger estate slows generic substitution and reduces near-term incentives to diversify sourcing away from brand-labeled FDF supply.
Patent estate components relevant to supply
Pristiq’s relevant patent clusters typically include:
- Active ingredient and salt form coverage
- Extended-release formulation and dissolution profile coverage
- Manufacturing process and/or particle engineering for API
- Method-of-use coverage that can affect regulatory strategy
How do Pristiq suppliers compare with other desvenlafaxine ER brands?
Answer: For desvenlafaxine ER competitors (brand or authorized generics), the most meaningful supplier comparisons are:
- API supplier qualification and ER dissolution equivalence controls
- FDF manufacturing sites and process validation acceptance
- Packaging and NDC-level labeler/manufacturer mapping
What differs in competitive supply chains
- Some firms use different ER excipient systems that require separate qualification
- Some use alternative compression and coating process controls that affect dissolution and stability
- Site constraints can shift during tech transfer, changing supplier risk profiles
Key Takeaways
- “Suppliers for Pristiq” in procurement terms map first to finished dosage form manufacturers and their associated packaging/distribution sites, with drug substance (desvenlafaxine succinate) suppliers further upstream.
- Supplier visibility is highest for FDF and labeler/NDC-linked manufacturers in FDA-linked product materials; upstream API and excipient suppliers are less fully disclosed publicly.
- Future supplier switching is most sensitive to generic entry and patent/exclusivity events, which affect market share and thus contractual procurement priorities.
FAQs
- How do I identify the Pristiq manufacturer for a specific NDC?
- Are Pristiq tablet excipients sourced from named vendors on public FDA records?
- What is the difference between the desvenlafaxine ER API supplier and the finished-dose supplier?
- How does ANDA approval timing affect Pristiq procurement and supplier diversification?
- What manufacturing site changes for Pristiq should procurement teams monitor?
References
- FDA. “Drug Approval Reports and Product Labeling (Pristiq, desvenlafaxine succinate extended-release).” US Food and Drug Administration.
- FDA. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (Pristiq, desvenlafaxine succinate extended-release).” US Food and Drug Administration.
- FDA. “NDC Directory (Pristiq labeler and product/manufacturer mapping).” US Food and Drug Administration.
